Nemaura Medical Producing What Was Thought To Be Implausible

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Nemaura Medical NMRD has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface of the skin. Its revolutionary sugarBEAT(R) constant glucose monitoring (“CGM”) device provides users with non-invasive glucose monitoring. Recently, the company released the MiBoKo application, an offering that uses a non-invasive glucose sensor to determine users’ Metabolic Score, which is based on glucose tolerance or insulin resistance. Nemaura Medical’s efforts come amid a rise in the global diabetic population that has led to an exponential increase in the use of CGM devices, which provide both diabetic and pre-diabetic individuals with early detection of hypo and hyperglycemic conditions. A report forecasts the blood glucose monitoring system market to grow at a CAGR of 9.6% between 2021 and 2026 to reach $27.2 billion (https://ibn.fm/tIn7l). A recent article reads, “With constant glucose monitoring devices rapidly gaining proponents amongst endocrinologists and the public alike, Nemaura Medica has set out to produce what was hitherto thought to be implausible — a revolutionary product through which patients can monitor their sugar levels without needles or the need for the individual to puncture their skin.”

To view the full article, visit https://ibn.fm/WKjAK

About Nemaura Medical Inc.

Nemaura is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched Miboko, a new program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Image sourced from Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.